Episode Details

Back to Episodes
Pharmaceutical Executive Daily: Hanmi Licenses HM17321 to Genentech

Pharmaceutical Executive Daily: Hanmi Licenses HM17321 to Genentech

Published 2 months, 3 weeks ago
Description
Hanmi Pharm licenses its obesity drug candidate HM17321 to Genentech, James LaValle weighs in after FDA advisors back most nominated peptides for the compounding bulks list, and Ivo Carre examines how tau- and microglia-targeted therapies are reshaping the Alzheimer's pipeline beyond amyloid.
Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us